Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3181 |
Name | oligodendroglioma |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | DOID:3182 |
Path | disease disease of cellular proliferation cancer cell type cancer high grade glioma oligodendroglioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
IDH1 R132H | Decitabine | oligodendroglioma | sensitive | detail... |
IDH1 mutant | N/A | oligodendroglioma | not applicable | detail... |
IDH2 mutant | N/A | oligodendroglioma | not applicable | detail... |
FGFR1 M563I FGFR1 K687E | Futibatinib | oligodendroglioma | predicted - sensitive | detail... |
IDH1 act mut | Vorasidenib | oligodendroglioma | sensitive | detail... |
IDH2 act mut | Vorasidenib | oligodendroglioma | sensitive | detail... |
IDH1 act mut | Ivosidenib | oligodendroglioma | sensitive | detail... |
IDH2 act mut | Ivosidenib | oligodendroglioma | sensitive | detail... |
IDH1 R132X | Vorasidenib | oligodendroglioma | sensitive | detail... |
IDH2 R172X | Vorasidenib | oligodendroglioma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00303849 | Phase Ib/II | Filgrastim Etoposide + Melphalan Carboplatin Pegfilgrastim | Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma | Completed | USA | 0 |
NCT01052363 | Phase I | Bevacizumab + Fosbretabulin | OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas | Withdrawn | USA | 0 |
NCT01140568 | Phase II | Nilotinib | Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas | Completed | USA | 0 |
NCT01188096 | Phase II | Poly ICLC | A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas | Completed | USA | 0 |
NCT01339039 | Phase I | Bevacizumab + Plerixafor | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | Terminated | USA | 0 |
NCT01392209 | Phase I | Bevacizumab | Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma | Completed | USA | 0 |
NCT01434602 | Phase Ib/II | Everolimus + Sorafenib | Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas | Completed | USA | 0 |
NCT01721577 | Phase Ib/II | AXL1717 | Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas | Terminated | USA | 0 |
NCT01884740 | Phase Ib/II | Bevacizumab + Cetuximab | Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age | Terminated | USA | 0 |
NCT01891747 | Phase I | Bevacizumab + Temozolomide | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | Completed | USA | 0 |
NCT01977677 | Phase Ib/II | Temozolomide Plerixafor | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | Completed | USA | 0 |
NCT01999270 | Phase I | Bevacizumab + Irinotecan | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | Completed | USA | 0 |
NCT02052778 | Phase Ib/II | Futibatinib | A Study of TAS-120 in Patients With Advanced Solid Tumors | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 4 |
NCT02078648 | Phase Ib/II | SL-701 Poly ICLC Bevacizumab | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | Completed | USA | 0 |
NCT02101905 | Phase I | Lapatinib | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | Completed | USA | 0 |
NCT02238496 | Phase II | Perifosine + Temsirolimus | Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Completed | USA | 0 |
NCT02423525 | Phase I | Afatinib | Safety Study of Afatinib for Brain Cancer | Completed | USA | 0 |
NCT02549833 | Phase I | GBM6-AD lysate protein vaccine + Poly ICLC | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | Completed | USA | 0 |
NCT02924038 | Phase I | IMA950 + Poly ICLC Varlilumab | A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG) | Terminated | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT03343197 | Phase I | Ivosidenib Vorasidenib | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma | Active, not recruiting | USA | 0 |
NCT03514069 | Phase I | Ruxolitinib Ruxolitinib + Temozolomide | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | Active, not recruiting | USA | 0 |
NCT03969706 | Phase II | Abemaciclib | Abemaciclib in Patients With Oligodendroglioma | Active, not recruiting | USA | 0 |
NCT03975829 | FDA approved | Dabrafenib + Trametinib | Pediatric Long-Term Follow-up and Rollover Study | Active, not recruiting | USA | SWE | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 2 |
NCT03991832 | Phase II | Durvalumab + Olaparib | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID) | Recruiting | CAN | 0 |
NCT04164901 | Phase III | Vorasidenib | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | 1 |
NCT04295759 | Phase I | INCB7839 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | Active, not recruiting | USA | 0 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04691960 | Phase II | Metformin | A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging | Recruiting | USA | 0 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Active, not recruiting | USA | 0 |
NCT04910022 | Phase Ib/II | NMS-03305293 + Temozolomide Lomustine | Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma | Recruiting | USA | NLD | ITA | CHE | 0 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT04978727 | Phase I | SurVaxM | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Recruiting | USA | CAN | 0 |
NCT05267106 | Phase II | Pemigatinib | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | 1 |
NCT05297864 | Phase II | Niraparib | PARP Inhibition for Gliomas (PI-4G or pi4g) | Terminated | USA | 0 |
NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Terminated | USA | 0 |
NCT05561374 | Phase I | OKN-007 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma | Active, not recruiting | USA | 0 |
NCT05956821 | Phase Ib/II | Bevacizumab + Cetuximab | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | Recruiting | USA | 0 |
NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |